Sentiment-Signal
10,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Unternehmen & Branche
| Name | Beta Bionics, Inc. |
|---|---|
| Ticker | BBNX |
| CIK | 0001674632 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Equipment & Services |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 445,2 Mio. USD |
| Beta | 5,06 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 27,626,000 | -21,895,000 | -0.49 | 304,417,000 | 271,245,000 |
| 2025-12-31 | 10-K | 100,251,000 | -73,200,000 | -1.81 | 328,743,000 | 287,610,000 |
| 2025-09-30 | 10-Q | 27,253,000 | -14,209,000 | -0.33 | 330,046,000 | 294,760,000 |
| 2025-06-30 | 10-Q | 23,238,000 | -16,869,000 | -0.39 | 329,971,000 | 301,633,000 |
| 2025-03-31 | 10-Q | 17,639,000 | -28,656,000 | -0.93 | 338,024,000 | 313,752,000 |
| 2024-12-31 | 10-K | 65,124,000 | -54,756,000 | -8.60 | 149,645,000 | -245,360,000 |
| 2024-09-30 | 10-Q | 16,705,000 | -9,736,000 | -1.46 | -228,848,000 | |
| 2024-06-30 | 10-Q | 15,046,000 | -14,463,000 | -2.37 | -221,213,000 | |
| 2024-03-31 | 10-Q | 12,933,000 | -12,449,000 | -2.07 | -214,323,000 | |
| 2023-12-31 | 10-K | 11,995,000 | -44,099,000 | -8.31 | 110,040,000 | -203,105,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -353 | 11.57 | -4,084.21 | -6,2% | |
| 2026-03-02 | Russell Steven Jon | Officer, Chief Medical Officer | Open Market Sale | -1,026 | 12.36 | -12,683.00 | -19,3% | |
| 2026-03-02 | Mensinger Mike | Officer, Chief Product Officer | Open Market Sale | -1,064 | 12.36 | -13,152.74 | -20,0% | |
| 2026-03-02 | Feider Stephen | Officer, Chief Financial Officer | Open Market Sale | -1,428 | 12.36 | -17,652.36 | -26,9% | |
| 2026-03-02 | Saint Sean | Director, Officer, President & CEO | Open Market Sale | -3,384 | 12.36 | -41,831.65 | -63,7% | |
| 2026-03-02 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -834 | 12.36 | -10,309.57 | -15,7% | |
| 2026-01-06 | Mensinger Mike | Officer, Chief Product Officer | Open Market Sale | -2,200 | 30.10 | -66,221.10 | -100,8% | |
| 2026-01-02 | Mensinger Mike | Officer, Chief Product Officer | Open Market Sale | -600 | 30.20 | -18,118.14 | -27,6% | |
| 2026-01-02 | Mensinger Mike | Officer, Chief Product Officer | Open Market Sale | -7,200 | 29.56 | -212,832.00 | -324,0% | |
| 2026-01-02 | Feider Stephen | Officer, Chief Financial Officer | Open Market Sale | -20,000 | 29.53 | -590,680.00 | -899,1% | |
| 2025-12-04 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -2,061 | 30.66 | -63,192.32 | -96,2% | |
| 2025-12-02 | Feider Stephen | Officer, Chief Financial Officer | Open Market Sale | -1,427 | 29.34 | -41,862.33 | -63,7% | |
| 2025-12-02 | Russell Steven Jon | Officer, Chief Medical Officer | Open Market Sale | -1,025 | 29.34 | -30,069.30 | -45,8% | |
| 2025-12-02 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -856 | 29.34 | -25,111.53 | -38,2% | |
| 2025-12-02 | Saint Sean | Director, Officer, President & CEO | Open Market Sale | -3,278 | 29.34 | -96,163.08 | -146,4% | |
| 2025-12-02 | Mensinger Mike | Officer, Chief Product Officer | Open Market Sale | -1,063 | 29.34 | -31,184.06 | -47,5% | |
| 2025-12-01 | Lezack Adam | Director | Open Market Sale | -500 | 29.91 | -14,955.00 | -22,8% | |
| 2025-12-01 | Lezack Adam | Director | Open Market Sale | -906 | 29.35 | -26,587.75 | -40,5% | |
| 2025-12-01 | Palasis Maria | Director | Open Market Sale | -500 | 29.96 | -14,982.00 | -22,8% | |
| 2025-12-01 | Palasis Maria | Director | Open Market Sale | -906 | 29.33 | -26,570.17 | -40,4% | |
| 2025-10-31 | Lezack Adam | Director | Open Market Sale | -1,368 | 26.85 | -36,727.24 | -55,9% | |
| 2025-10-31 | Lezack Adam | Director | Open Market Sale | -38 | 27.70 | -1,052.60 | -1,6% | |
| 2025-10-31 | Palasis Maria | Director | Open Market Sale | -119 | 27.45 | -3,266.57 | -5,0% | |
| 2025-10-31 | Palasis Maria | Director | Open Market Sale | -1,287 | 26.86 | -34,567.28 | -52,6% | |
| 2025-10-03 | Feider Stephen | Officer, Chief Financial Officer | Open Market Sale | -1,154 | 22.28 | -25,708.58 | -39,1% | |
| 2025-10-03 | Feider Stephen | Officer, Chief Financial Officer | Open Market Sale | -3,828 | 21.52 | -82,367.84 | -125,4% | |
| 2025-10-01 | Feider Stephen | Officer, Chief Financial Officer | Open Market Sale | -14,918 | 20.76 | -309,697.68 | -471,4% | |
| 2025-10-01 | Feider Stephen | Officer, Chief Financial Officer | Open Market Sale | -100 | 21.08 | -2,108.00 | -3,2% | |
| 2025-09-05 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -11,411 | 20.56 | -234,656.95 | -357,2% | |
| 2025-09-04 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -6,818 | 19.97 | -136,180.00 | -207,3% | |
| 2025-09-02 | Russell Steven Jon | Officer, Chief Medical Officer | Open Market Sale | -1,015 | 18.86 | -19,146.15 | -29,1% | |
| 2025-09-02 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -848 | 18.86 | -15,995.99 | -24,3% | |
| 2025-08-19 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -16,158 | 16.61 | -268,376.30 | -408,5% | |
| 2025-06-02 | Russell Steven Jon | Officer, Chief Medical Officer | Open Market Sale | -94 | 18.69 | -1,756.95 | -2,7% | |
| 2025-06-02 | Russell Steven Jon | Officer, Chief Medical Officer | Open Market Sale | -660 | 18.15 | -11,978.27 | -18,2% | |
| 2025-06-02 | Russell Steven Jon | Officer, Chief Medical Officer | Open Market Sale | -285 | 17.03 | -4,852.98 | -7,4% | |
| 2025-06-02 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -551 | 18.15 | -10,000.04 | -15,2% | |
| 2025-06-02 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -238 | 17.03 | -4,052.66 | -6,2% | |
| 2025-06-02 | Hopman Mark | Officer, Chief Commercial Officer | Open Market Sale | -79 | 18.69 | -1,476.59 | -2,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.